Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-cash Items (2017 - 2022)

Historic Non-cash Items for Ani Pharmaceuticals (ANIP) over the last 7 years, with Q4 2022 value amounting to $3.9 million.

  • Ani Pharmaceuticals' Non-cash Items fell 4300.03% to $3.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $3.9 million, marking a year-over-year decrease of 4300.03%. This contributed to the annual value of $3.9 million for FY2022, which is 53099.51% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Non-cash Items of $3.9 million as of Q4 2022, which was down 4300.03% from $6.8 million recorded in Q4 2021.
  • In the past 5 years, Ani Pharmaceuticals' Non-cash Items registered a high of $6.8 million during Q4 2021, and its lowest value of $372000.0 during Q4 2020.
  • Over the past 5 years, Ani Pharmaceuticals' median Non-cash Items value was $3.9 million (recorded in 2022), while the average stood at $4.0 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Non-cash Items plummeted by 9449.79% in 2020 and then soared by 172419.35% in 2021.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Non-cash Items stood at $2.2 million in 2018, then surged by 204.41% to $6.8 million in 2019, then tumbled by 94.5% to $372000.0 in 2020, then soared by 1724.19% to $6.8 million in 2021, then tumbled by 43.0% to $3.9 million in 2022.
  • Its Non-cash Items was $3.9 million in Q4 2022, compared to $6.8 million in Q4 2021 and $372000.0 in Q4 2020.